Abstracts tagged "biomarkers and rituximab"

Abstract Number: 595 • 2018 ACR/ARHP Annual Meeting
Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab
Sheila Melchor¹, Esther Rodriguez-Almaraz², Jose L. Pablos³ and Patricia Carreira⁴, ¹Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain., Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Servicio de Reumatología, Rheumatology Department, Hospital 12 de Octubre, Spain, Madrid, Spain, ⁴Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: Rituximab (RTX) is directed against CD20 antigens in B lymphocytes (BL), producing selective depletion of BL, not affecting mature plasmatic cells, without immediate effect…
Abstract Number: 560 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome
Gwenny M. Verstappen¹, Johan Bijzet¹, Jolien F. van Nimwegen¹, Martha S. van Ginkel¹, Arjan Vissink², Hendrika Bootsma¹ and Frans G.M. Kroese¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains…
Abstract Number: 2118 • 2016 ACR/ARHP Annual Meeting
Rituximab Treated Non Responder Rheumatoid Arthritis Patients Are Generating a New Autoantibody Repertoire
Zoltan Konthur¹, Melvin Michael Wiemkes², Thomas Häupl³, Gerd R. Burmester⁴ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann Rheum Dis.…
Abstract Number: 3105 • 2016 ACR/ARHP Annual Meeting
Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus
Ricardo Marques¹, Laura Heretiu², David A. Isenberg³, Maria J. Leandro³ and Geraldine Cambridge³, ¹Serviço de Medicina Interna B, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ²Medicine, Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Rituximab (RTX) has been used off-label in refractory SLE with variable clinical outcomes in different cohorts, with no predictive response markers available. However, the…
Abstract Number: 784 • 2013 ACR/ARHP Annual Meeting
IgG4+ Plasmablasts Are A Novel Biomarker In IgG4-Related Disease
Mollie Carruthers¹, Hamid Mattoo², Zachary S. Wallace³, Vinay Mahajan⁴, Shiv Pillai⁵ and John H. Stone¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Oncology, Massachusetts General Hospital, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disorder that responds to B cell depletion with rituximab (RTX). We detected IgG4+ plasmablasts in the sera of…